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Insomnia current diagnosis: an appraisal
Diagnóstico atual de insônia: uma apreciação
Philippe Joaquim Oliveira Menezes Macêdo1, Gisele Schenkel de Moura Leite Neves1,  
Dalva Lucia Rollemberg Poyares2, Marleide da Mota Gomes1
RESUMO
A insônia crônica é o transtorno do sono mais comum em adultos, 
e seu diagnóstico é fundamental para o manejo clínico adequado. 
O principal objetivo deste trabalho é apresentar, em relação à insô-
nia, as definições publicadas recentemente segundo as novas classi-
ficações internacionais, como a Classificação Internacional de Distúr-
bios do Sono – Terceira Edição e o Manual Diagnóstico e Estatístico 
de Transtornos Mentais – Quinta Edição. Pela primeira vez, essas 
classificações são congruentes a respeito de seus critérios diagnós-
ticos, pois ambas apresentam a insônia como uma doença em si e 
a dividem em aguda, crônica e outras. Isso enfatiza a necessidade 
de uma abordagem específica da insônia. Além do mais, é necessá-
rio reconhecer os insones com estado fisiológico de hiperalerta que 
podem ser identificados por medidas objetivas (tempo total de sono 
curto, por exemplo). Esses pacientes podem ter pior prognóstico, por 
causa do maior risco de desenvolver condições cardiometabólicas e 
comprometimento neurocognitivo. O diagnóstico da insônia é feito 
principalmente com base em dados clínicos (anamnese e exame fí-
sico), e o uso de diário de sono e questionários (tais como o Índice 
de Gravidade de Insônia) pode ajudar na avaliação desses pacientes. 
Análises objetivas, como aquelas obtidas pela polissonografia, não 
são rotineiramente necessárias na maioria dos casos, exceto quando 
há a suspeita de outro distúrbio do sono.
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ABSTRACT
Chronic insomnia is the most common sleep disorder in adults and 
its diagnosis is fundamental for adequate clinical management. The 
aim of this paper is to present recently published definitions of in-
somnia according to current international classifications, such as the 
International Classification of Sleep Disorders – Third Edition and the 
Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition. 
For the first time, these classifications are congruent related to their 
diagnostic criteria; both present insomnia as a distinct disorder and 
divide it into acute, chronic and other. This emphasizes the necessi-
ty of a specific insomnia approach. Furthermore, it is necessary to 
recognize those insomniacs with physiological hyperarousal, which 
may be identified by objective measures (short total sleep time, for 
instance). These patients may have poorer outcome, as they are at 
higher risk of developing cardiometabolic conditions and neuro-
cognitive impairment. Diagnosis is primarily made on a clinical ba-
sis (anamnesis and physical examination), while sleep diaries and 
questionnaires (such as Insomnia Severity Index) can help evaluate 
these patients. Objective measures, such as polysomnography, are 
not required in most cases, except when suspicion of another sleep 
disorder arises.
Keywords: Insomnia, comorbid insomnia, short sleep duration.
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INTRODUCTION
The adverse consequences of sleep disruption on hu-
man physiology are well known as they compromise 
the individual’s health and well-being. Short sleep 
has been linked to obesity, hypertension, altered 
metabolic/endocrine profile (such as diabetes), 
coronary heart disease and increased mortality risk.1 
Furthermore, many studies demonstrate an associa-
tion between untreated or underlying sleep disorder 
with daytime dysfunction, cognitive impairment, 
metabolic disorders, stroke, sudden death during 
sleep and higher risk of fatal and nonfatal cardiovas-
cular diseases.2-8 Insomnia is the most prevalent sleep 
disorder in the general population.9 It is currently 
defined, according to the International Classifica-
tion of Sleep Disorders – Third Edition (ICSD-3) 
criteria, as persistent difficulty with sleep initiation, 
duration, consolidation or quality that occurs despite 
the opportunity and circumstances for sleep, which 
results in some type of disability during the day.10 
Despite the relevance of insomnia in clinical prac-
tice, it is undervalued by most health professionals 
and patients. Additionally, due to the wide variety 
of definitions used in scientific papers, it is difficult 
to compare outcomes and risk factors in a meaning-
ful way.11 Nevertheless, as a symptom, syndrome or 
disease, it has a significant negative impact on social 
life, task performance and daytime functioning with 
higher odds of errors or accidents.12,13 Therefore, the 
objective of this paper is to appraise the most recent 
international insomnia classifications and raise some 
issues regarding insomnia diagnosis.
PREVALENCE OF INSOMNIA COMPLAINTS, 
SYMPTOMS, SYNDROME AND DISORDER
Ohayon and Reynolds12 assessed the prevalence of 
insomnia according to various definitions in a Euro-
pean population aged 15-years or older. They found 
that one-third (34.5%) of individuals had at least one 
symptom of insomnia: 23.1% experienced difficulty 
maintaining sleep (the most common symptom), 
whilst 10.9%, 12.3% and 11.1% experienced diffi-
culty initiating sleep, early morning awakening and 
non-restorative sleep, respectively. When applying 
DSM-IV criteria, 9.8% were found to have insomnia 
disorder, and after exclusion of other clinical and psy-
chiatric conditions, 3% were diagnosed with primary 
insomnia.12 In a study evaluating 1,042 subjects in 
Brazil, 15% were found to have insomnia based on 
DSM-IV criteria, while 32% were found to experi-
ence insomnia using objective measures.14 Objective 
insomnia was defined as meeting one of the follow-
ing criteria: sleep onset latency > 30 minutes (sleep 
initiating insomnia), wake after sleep onset lasting > 
30 minutes (sleep maintenance insomnia), total sleep 
time < 360 minutes and a terminal wakefulness > 30 
minutes (insomnia with too short duration of sleep 
or early morning awakening), or a combination of 
the previous quantitative criteria (mixed disorder). 
CORRELATES OF INSOMNIA, COSTS AND QUALITY 
OF LIFE
The isolated occurrence of insomnia disorder in the 
general population is an uncommon event. It is typi-
cally followed by multiple, recurrent and persistent 
health problems, which increase demand for health 
care and raise direct and indirect costs related to 
insomnia management.3,4,11,15 Considering the high 
prevalence of this sleep disturbance and its burden 
on public health, the consequences of untreated dis-
ease for both the individual and society can be disas-
trous. Untreated disease can lead to increased work 
absenteeism related to all causes of illness (clinical 
and psychiatric), lower task performance and higher 
odds of accidents.4,5,16 The risk of non-intentional 
fatal injuries increases in individuals who experience 
difficulty falling asleep, maintaining sleep or non-
restorative sleep, and also increases when there is an 
association of two or more of these symptoms.17 
According to social and demographic data, insom-
nia is usually more common in women than men, with 
a woman/man ratio of 1.4 for insomnia symptoms 
(1.7 after 45 years of age), and of 2.0 for insomnia 
diagnosis.6,11 Old individuals have also higher odds of 
developing insomnia,18 as well as those with impaired 
marital status (widow, divorced, separated), unemplo-
yed or retired.11 When considering only newly diagno-
sed patients, Singareddy et al.6 found that the incidence 
of insomnia was higher in younger individuals. Quality 
of life of insomniacs is significantly impaired, affecting 
their overall subjective sense of physical well-being. 
This is probably secondary to psychiatric or physical di-
sorders, medications and psychosocial issues, with some 
studies showing a positive effect of insomnia treatment 
and management of comorbidities on quality of life.19 
Insomnia current diagnosis
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Insomnia disorder and insomnia symptoms are 
commonly related to neuropsychiatric illness, es-
pecially mood disorders.11 The majority of subjects 
with major depression (80%) develop insomnia 
symptoms in the course of their disease, exhibiting 
a four-fold risk when compared with the general 
population.11,12 Anxiety disorder is also more com-
mon in insomniacs, while insomnia can facilitate or 
trigger anxiety and depressive disorder.11,12 Smoking 
positively correlates with difficulty in achieving sleep 
initiation and maintenance and may lead to short 
sleep duration (< 6 hours).11 Alcohol consumption 
may at first accelerate sleep onset, but chronic use 
will likely increase sleep disruption and abolish its 
effect on sleep initiation.11 
It is possible to define two subgroups of insomnia 
patients with the presence or absence of physiologi-
cal hyperarousal, which can be identified by objective 
measures, as short sleep duration and mean latency > 
8 minutes on Multiple Latency Sleep Test (MLST).7,8 
Patients with hyperarousal/hyperalert state express 
a higher risk of cardiometabolic conditions, such as 
hypertension, impaired heart rate variability and pre
-ejection period and type 2 diabetes – all of which in-
crease mortality in these individuals.1,7 Furthermore, 
these patients are more likely to develop neurocog-
nitive impairment, poorer psychiatric comorbidity 
and a more severe phenotype of insomnia.7 While 
evaluating the performance of insomniacs and nor-
mal sleepers using computer-administered reaction 
time tasks, Edinger et al.8 demonstrated that those 
with insomnia and physiological hyperarousal (defi-
ned by mean latency on MLST > 8 minutes) had 
lower performance on tasks requiring attention. This 
was evidenced by higher error rate, showing cogni-
tive deficit.8 
CURRENT CLASSIFICATIONS
International Classification of Sleep Disorders – 
Third Edition (ICSD-3, tables 1 and 2)10 
The last update of the ICSD occurred in 2014 
and its content revisions were in line with the 
DSM-V. One of the major changes includes a sin-
gle entry for the disorders of insomnia called “in-
somnia disorder”. Compared to ICSD-2, ICSD-3 
has a less extensive diagnostic subtyping, which 
applies to patients with and without comorbidities, 
regardless of the disruptive potential of the comor-
bidities. Among adults with insomnia, sleep com-
plaints typically include more difficulty in initiating 
or maintaining sleep. Concerns over long periods 
of nocturnal wakefulness, insufficient amounts of 
night-time sleep or poor quality of sleep often ac-
company these complaints. In children, this sleep 
disorder is frequently reported by caregivers and 
characterized by resistance to sleep, frequent noc-
turnal awakenings, and/or an inability to sleep in-
dependently. 
Daytime consequences are reported by these sub-
jects, presumably caused by reduced nocturnal sleep 
or by some other common mechanism. Daytime 
symptoms often include fatigue, decreased mood 
or irritability, malaise and cognitive impairment. 
Among adults, chronic insomnia can impair social or 
occupational functioning and reduce quality of life. 
In children, it can lead to poor school performan-
ce, impaired attention and behavior disorders. It is 
not unusual for some patients to experience physical 
symptoms such as muscle tension, palpitations and 
headache. Despite daytime impairment, these pa-
tients usually don’t complain of excessive somnolen-
ce or report a high occurrence of naps. 
ICSD-3 includes three diagnostic categories for 
insomnia: chronic insomnia disorder (Table 1), di-
sorder of short-term insomnia (Table 2) and ano-
ther insomnia disorder. Chronic insomnia disorder 
is characterized by difficulty falling asleep and/or 
complaints of sleep maintenance associated with 
daytime impairment for at least three months. It is 
reserved for individuals whose sleep difficulties ex-
ceed frequency limits (at least three times per week) 
and minimum length to be associated with clinically 
significant morbidity. Of note, former chronic pri-
mary insomnia criteria (DSM IV) included symp-
toms occurring for at least one month. Short-term 
insomnia has a similar definition and is applied when 
the complaints or symptoms last less than three mon-
ths; when neither criterion is fulfilled, a definition of 
other insomnia disorder is used.
Diagnostic and Statistical Manual of Mental 
Disorders – Fifth Edition (DSM-V, table 3)20,21
DSM-V was launched in 2013 and is much like 
ICSD-3. Compared with DSM-IV-TR, DSM-V 
Macêdo PJOM et al.
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Table 1. Chronic insomnia disorder (ICSD-3)
Diagnostic Criteria
Criteria A-F must be met 
A. The patient reports, or the patient’s parent or caregiver observes, one or more of the following:
1. Difficulty initiating sleep.
2. Difficulty maintaining sleep.
3. Waking up earlier than desired.
4. Resistance to going to bed on appropriate schedule.
5. Difficulty sleeping without parent or caregiver intervention.
B. The patient reports, or the patient’s parent or caregiver observes, one or more of the following related to the night-time sleep difficulty:
1. Fatigue/malaise.
2. Attention, concentration or memory impairment.
3. Impaired social, family, occupational or academic performance.
4. Mood disturbance/irritability.
5. Daytime sleepiness.
6. Behavioral problems (e.g., hyperactivity, impulsivity, aggression).
7. Reduced motivation/energy/initiative.
8. Proneness for errors/accidents.
9. Concerns about or dissatisfaction with sleep.
C. The reported sleep/wake complaints cannot be explained purely by inadequate opportunity (i.e., enough time is allotted for sleep) or inadequate circumstances (i.e., the 
environment is safe, dark, quiet and comfortable) for sleep.
D. The sleep disturbance and associated daytime symptoms occur at least three times per week.
E. The sleep disturbance and associated daytime symptoms have been present for at least three months.
F. The sleep/wake difficulty is not better explained by another sleep disorder.
Table 2. Short-term insomnia disorder (ICSD-3)
Diagnostic Criteria
Criteria A-E must be met
A. The patient reports, or the patient’s parent or caregiver observes, one or more of the following:
1. Difficulty initiating sleep.
2. Difficulty maintaining sleep.
3. Waking up earlier than desired.
4. Resistance to going to bed on appropriate schedule.
5. Difficulty sleeping without parent or caregiver intervention.
B. The patient reports, or the patient’s parent or caregiver observes, one or more of the following related to the night-time sleep difficulty:
1. Fatigue/malaise.
2. Attention, concentration or memory impairment.
3. Impaired social, family, vocational or academic performance.
4. Mood disturbance/irritability.
5. Daytime sleepiness.
6. Behavioral problems (e.g., hyperactivity, impulsivity, aggression).
7. Reduced motivation/energy/initiative.
8. Proneness for errors/accidents.
9. Concerns about or dissatisfaction with sleep.
C. The reported sleep/wake complaints cannot be explained purely by inadequate opportunity (i.e., enough time is allotted for sleep) or inadequate circumstances (i.e., the 
environment is safe, dark, quiet and comfortable) for sleep.
D. The sleep disturbance and associated daytime symptoms have been present for less than three months.
E. The sleep/wake difficulty is not better explained by another sleep disorder.
mandates concurrent specification of coexisting con-
ditions and acknowledges the bidirectional and in-
teractive  effects between sleep disorder and coexist-
ing medical and mental disorders. This is a paradigm 
shift widely accepted in the field of sleep medicine, 
moving away from causal attributions between co-
existing disturbances. The diagnosis of primary in-
somnia disorder was replaced for insomnia disorder 
(Table 3), avoiding the differentiation between pri-
mary and secondary insomnia.
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International Classification of Diseases (ICD-10, 
Table 4)22
The latest edition of the International Classifica-
tion of Diseases assesses insomnia in a symptomatic 
definition with no considerations for daytime impair-
ment. It is considered among mental disorders (non-
organic insomnia, ICD-10 F.51.0) and neurological 
conditions (disorder of initiating sleep and maintain-
ing sleep – insomnia, ICD-10 G.47.0). According to 
the World Health Organization, the next revision of 
this classification is due in 2017. 
criteria (ICSD-3 and DSM-V) rather than relying on 
laboratory or polysomnographic findings. Consider-
ing the ethiopathogenics, this sleep disorder can be 
biological, environmental, behavioral or psychologi-
cal in nature. Therefore, it is important to perform 
a systematic search for predisposing and perpetuat-
ing factors, such as stress, clinical and mental con-
ditions (Table 5), inadequate sleep hygiene, use of 
substances/medications (caffeine, alcohol or drugs), 
circadian unsuitability (“jet lag”, shift work), sleep 
rumination, family history of insomnia or other sleep 
disturbance.9,13,23
Systematic sleep history helps to assess sleep-wake 
patterns over a period of weeks or months; charac-
terization of the premorbid baseline sleep patterns 
helps to establish a clinical relevance for insomnia 
complaints. Questions concerning chronotype and 
nocturnal sleep characteristics (e.g., sleep latency af-
ter lights out, occurrence and number of nocturnal 
awake during the night, rough time awake after sleep 
onset and what time the patient gets out of bed) are 
relevant to establish whether insomnia symptoms are 
present. The presence of mood changes, irritability, 
poor memory, fatigue, drowsiness, lack of energy, ge-
neral malaise and work or social impairment display 
the occurrence of daytime dysfunction. When related 
with insomnia complaints, the diagnosis of insomnia 
disorder is supported. Complete medical history is 
necessary to help identify medical and mental condi-
tions that can be the source or a secondary effect of 
this sleep disorder.13,23,24 
Although it is not mandatory for insomnia diag-
nosis, instruments can be used to help identify other 
comorbidities, measure severity of sleep complaints 
and as a comparison tool for treatment response. 
For example, the Insomnia Severity Index (ISI) is a 
subjective scale that assesses the intensity of insom-
nia symptoms. It has proven valuable for the diag-
nosis of this sleep disorder.25 The ISI contains seven 
questions, each one scoring a value between 0 and 4 
points, and the summation gives a total score ranging 
from 0 to 28. When the sum is higher than 14, cli-
nical insomnia can be defined with great specificity.26 
Assessment of sleep quality and daytime sleepiness is 
possible by using the Pittsburgh Sleep Quality Index 
and Epworth Sleepiness Scale, respectively. There 
are many questionnaires that can assess depression 
and anxiety symptoms, such as Beck Depression In-
ventory and Beck Anxiety Inventory, among others. 
Table 3. Insomnia disorder criteria (DSM-V)
Criteria A-H must be met
A. A predominant complaint of dissatisfaction with sleep quantity or quality, 
associated with one or more of the following symptoms:
1. Difficulty initiating sleep (in children, this may manifest as difficulty 
initiating sleep without a caregiver intervention).
2. Difficulty maintaining sleep, characterized by frequent awakenings or 
problems returning to sleep after awakenings (in children, this may manifest 
as difficulty returning to sleep without a caregiver intervention).
3. Early morning awakening with inability to return to sleep. 
B. The sleep disturbance causes clinically significant distress or impairment in 
social, occupational, educational, academic, behavioral or other important 
areas of functioning. 
C. The sleep difficulty occurs at least three nights per week.
D. The sleep difficulty is present for at least three months. 
E. The sleep difficulty occurs despite adequate opportunity for sleep.
F. The insomnia is not better explained by and does not occur exclusively 
during the course of another sleep disorder (e.g., narcolepsy, a breathing 
related sleep disorder, a circadian rhythm sleep-wake disorder, 
parasomnias).
G. The insomnia is not attributable to the psychological effects of a substance 
(e.g., drug abuse or a medication.) 
H. Coexisting mental disorders and medical conditions do not adequately 
explain the predominant complaint of insomnia.
Table 4. Nonorganic insomnia (ICD-10)
A. A complaint of difficulty falling asleep, maintaining sleep or non-refreshing 
sleep.
B. The sleep disturbance occurs at least three times per week for at least one 
month.
C. The sleep disturbance results in marked personal distress or interference 
with personal functioning in daily living.
D. Absence of any known causative organic factor, such as a neurological or 
other medical condition, psychoactive substance use disorder or a 
medication. 
HOW TO DIAGNOSE INSOMNIA
Insomnia diagnosis is based on clinical features pro-
vided by complete medical history, assessment of 
subjective sleep parameters, comprehensive physical 
examination and application of current classifications 
Macêdo PJOM et al.
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Quality of life is frequently impaired in these pa-
tients, and surveys that assess this parameter are very 
interesting, especially for treatment evaluation.24 
Patients with insomnia disorder are dissatisfied 
with sleep quantity or quality. This generally leads 
to overestimation of their sleep difficulty and unde-
restimation of actual sleep time, which can also lead 
to anticipatory anxiety and fear of not sleeping at all. 
For better elucidation of actual sleep pattern, a sle-
ep log prior to and during treatment must be con-
sidered. It is a descriptive subjective report of sleep, 
evaluating bedtime, sleep latency, number of awake-
nings, time awake after sleep onset, time in bed, total 
sleep time, sleep efficiency, nap times and medication 
use.24 There is a modest correlation between sleep 
logs and objective measures, with a tendency to un-
derestimate total sleep time and overestimate sleep 
latency. Nevertheless, it is still useful as an indicator 
of the patient’s sleep perception.15 If for some reason 
these individuals show difficulty completing the sleep 
log or great sleep misperception, actigraphy can be 
used as an objective measure.23,24 
Polysomnography is not routinely indicated for 
insomnia diagnosis, except when there is suspicion 
of other sleep disorders, such as sleep apnea, perio-
dic limb movement disorder and restless leg syndro-
me or former paradoxical insomnia.23,24 However, 
recent data suggest that insomniacs with objective 
hyperalert state might have a more severe insom-
nia phenotype, with a more chronic and progressive 
course. This could become a prognostic biomarker 
for clinical decision-making and therefore define a 
formal indication for standard sleep study in these 
patients.7 Nevertheless, there are not enough data 
to support routine polysomnography in patients 
with insomnia. 
CONCLUSION
Insomnia is a clinical condition that presents as per-
sistent difficulty in sleep initiation or sleep mainte-
nance or not feeling refreshed upon waking, with 
impaired social or occupational functioning. It is a 
prevalent sleep disorder in general population and 
may lead to serious repercussions to personal and 
social health. Current classifications (ICSD-3 and 
DSM-V) are highly similar and lessen confusion re-
garding insomnia definition, facilitating comparison 
of insomnia outcomes in future research endeavours. 
Special attention must be given for those insomni-
acs with hyperaroused state, who present more se-
vere cardiovascular and neuropsychiatric outcomes, 
therefore requiring closer assessment.
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Table 5. Comorbid clinical and mental conditions of insomnia (adapted 
from Schutte-Rodin et al., 2008)24
Neurological: Stroke, dementia, Parkinson’s disease, seizure disorders, 
headache disorders, traumatic brain injury, peripheral neuropathy, chronic pain 
disorders, neuromuscular disorders
Cardiovascular: Angina, congestive heart failure, dyspnoea, dysrhythmias
Pulmonary: COPD, emphysema, asthma, laryngospasm
Digestive: Reflux, peptic ulcer disease, cholelithiasis, colitis, irritable bowel 
syndrome
Genitourinary: Incontinence, benign prostatic hypertrophy, nocturia, enuresis, 
interstitial cystitis
Endocrine: Hypothyroidism, hyperthyroidism, diabetes mellitus
Musculoeskeletal: Rheumatoid arthritis, osteoarthritis, fibromyalgia, Sjögren 
syndrome, kyphosis
Reproductive: Pregnancy, menopause, menstrual cycle variations
Sleep disorders: Obstructive sleep apnea, central sleep apnea, restless leg 
syndrome, periodic limb movement disorder, circadian rhythm sleep disorders, 
parasomnias, bruxism
Mental: Depression, anxiety, psychotic disorders, attention deficit disorder, 
personality disorder
Substance use/abuse/withdrawal: 
Anxiolytics and antidepressants: SSRIs (fluoxetine, paroxetine, sertraline, 
citalopram, escitalopram, fluvoxamine), venlafaxine, duloxetine, monoamine 
oxidase inhibitors
Stimulants: Caffeine, methylphenidate, amphetamine derivatives, ephedrine 
and derivatives, cocaine
Descongestants: Pseudoephedrine, phenylephrine, phenylpropanolamine
Narcotic: Oxycodone, codeine, propoxyphene




Other: Allergies, rhinitis, sinusites
Insomnia current diagnosis
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